Tectonic Therapeutic has appointed Dr.

Longeveron announced that results from its Phase

Recursion Pharmaceuticals, a clinical‑stage Tec

Startup aims to ‘unlock prevention’ by combi

Multiple biotechs and academic institutions amon

A second milestone for Scribe and Lilly highligh

Syndex pairs a fresh diagnostic approach with $1

Novo Nordisk’s new partnership with Bob Langer

Life Time reported total revenue of $745.

Investment signals shift toward biochemical moni

Healthtech firm to co-lead scientific program fo

Recruitment for Phase 1 trial of mRNA therapy be

Ultra-small plastic particles detected in human

Policy shift favors one pivotal trial, aiming to

The personal care industry is quietly reorganizi

Startups building science-grounded, consumer-rea

New AI model EVA accelerates drug discovery in i

Insilico CEO Alex Zhavoronkov explains how machi

A once-a-month GLP-1/GIP drug candidate moves in

Study finds GPT-powered autonomous lab reduced e

Serina Therapeutics announced the enrollment of t

WELL Health Technologies Corp and HEALWELL AI Inc

Lario Therapeutics has been awarded USD 2.

A clinical trial conducted by Novos found that it

The United States has approved a combination of C

Precision nutrition pioneer L-Nutra will bring f

Evelyne Bischof on why credible training of doct

Paragon’s latest venture targets Alzheimer’s

Sava demonstrates its tiny, minimally invasive d

From a rare 14-month survival gain to a 65% lowe

A comprehensive competitive landscape analysis co

Research covering the sickle cell disease sector

A recent industry analysis finds that the global

Human Longevity, Inc.

Immortal Dragons, a Singapore‑based longevity i

Research indicates the global fallopian tube canc

Fresh backing from Michael J Fox Foundation and

Foodhak is using AI to make everyday eating more

New non-invasive wearable that uses AI and biose

Company aims to drug the ‘undruggable’ with

Declining stem cell release may reshape resilien

A global analysis forecasts the longevity market’s revenue to exceed US$740 billion in 2026 with sustained growth through to 2036. The research highlights a structural shift from consumer wellness offerings to healthcare‑oriented solutions supported by insurers, employers, health systems and pharmaceutical firms. This trend is creating demand for integrated platforms that support early risk detection, preventive care and ongoing clinical engagement. Technological advances in artificial intelligence, genomics and regenerative medicine are identified as key forces shaping the longevity market’s trajectory. AI‑enabled platforms are being used to analyse complex biological and longitudinal data to speed early‑stage discovery and prioritise therapeutic targets. Progress in gene‑editing and biomarker profiling is facilitating more targeted interventions for age‑related conditions under regulatory oversight. Regenerative medicine programmes are advancing cellular and tissue repair approaches aimed at improving resilience in major physiological systems. Leading companies in the field include AbbVie Inc., Alkahest, Inc., CELLINK, Elysium Health, Juvenescence Ltd., Insilico Medicine Life Biosciences, Inc., Rejuvenate Bio, Serina Therapeutics, Inc., Bristol-Myers Squibb Company, GSK plc, and others. Digital health tools, remote monitoring technologies and longevity clinic models are reinforcing market adoption by enabling proactive, data‑driven management of healthspan. Wearable devices that track physiological indicators and clinics combining diagnostics with AI‑guided…

Sana Biotechnology has appointed Brian Piper as E

Theriva Biologics has granted Rasayana Therapeuti

NeuroSense Therapeutics Ltd announced updated lon

EyePoint Pharmaceuticals has appointed Michael Ca

Zifo Technologies and Maze Therapeutics have ente

GenSight Biologics has expanded its Regulatory Af

Scribe Therapeutics has achieved a second success

UK Biobank study connects gray matter difference